Vestor Capital LLC Buys 7,484 Shares of McKesson Co. (NYSE:MCK)

Vestor Capital LLC boosted its stake in shares of McKesson Co. (NYSE:MCK) by 968.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,257 shares of the company’s stock after purchasing an additional 7,484 shares during the quarter. Vestor Capital LLC’s holdings in McKesson were worth $4,706,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Mizuho Securities USA LLC boosted its position in McKesson by 43.1% during the fourth quarter. Mizuho Securities USA LLC now owns 12,031 shares of the company’s stock worth $6,857,000 after purchasing an additional 3,622 shares during the period. Virtu Financial LLC acquired a new stake in shares of McKesson during the fourth quarter worth $570,000. Quantbot Technologies LP lifted its holdings in shares of McKesson by 60.8% during the fourth quarter. Quantbot Technologies LP now owns 20,201 shares of the company’s stock worth $11,513,000 after buying an additional 7,638 shares in the last quarter. ZEGA Investments LLC acquired a new stake in shares of McKesson during the fourth quarter worth $1,831,000. Finally, Millstone Evans Group LLC acquired a new stake in shares of McKesson during the fourth quarter worth $28,000. 85.07% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Brian S. Tyler sold 8,961 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $597.99, for a total transaction of $5,358,588.39. Following the transaction, the chief executive officer now directly owns 60,664 shares of the company’s stock, valued at $36,276,465.36. This represents a 12.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Leann B. Smith sold 579 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total value of $331,645.41. Following the completion of the transaction, the executive vice president now directly owns 864 shares in the company, valued at approximately $494,890.56. This represents a 40.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,689 shares of company stock valued at $11,187,351 over the last ninety days. 0.11% of the stock is currently owned by corporate insiders.

McKesson Trading Down 1.0 %

NYSE MCK opened at $659.45 on Friday. McKesson Co. has a 12 month low of $464.42 and a 12 month high of $670.79. The stock has a market cap of $82.65 billion, a P/E ratio of 30.19, a P/E/G ratio of 1.29 and a beta of 0.52. The stock’s fifty day moving average price is $616.14 and its 200-day moving average price is $574.33.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. As a group, analysts forecast that McKesson Co. will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date of this dividend is Monday, March 3rd. McKesson’s payout ratio is currently 13.00%.

Wall Street Analysts Forecast Growth

MCK has been the subject of a number of research reports. Morgan Stanley lifted their target price on McKesson from $612.00 to $642.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Bank of America lowered their target price on McKesson from $680.00 to $650.00 and set a “buy” rating for the company in a research note on Monday, January 6th. StockNews.com downgraded McKesson from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Evercore ISI boosted their price target on McKesson from $650.00 to $675.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Finally, Wells Fargo & Company upped their target price on McKesson from $641.00 to $691.00 and gave the company an “equal weight” rating in a report on Friday, March 14th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $649.36.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.